HIV Supplemental Surveillance Report: Enhanced Perinatal Surveillance Georgia 2005-2010



This Enhanced Perinatal Surveillance Report, Georgia 2005-2010 is published by the Georgia Department of Public Health (GDPH), HIV/AIDS Epidemiology Program (HAEP), 2 Peachtree Street, Atlanta Georgia 30303.

Data are presented for a facility-based sample of cases of HIV infection among pregnant women delivering a live birth in Georgia during 2005-2010. All data are provisional.

The Enhanced Perinatal Surveillance Report, Georgia 2005-2010 is not copyrighted and may be used and reproduced without permission. Citation of the source is, however, appreciated.

#### Suggested citation:

Georgia Department of Public Health, HIV/AIDS Epidemiology Program Enhanced Perinatal Surveillance Report, Georgia 2005-2010. Published October 2013

On the Web: DPH.ga.gov/epi/HIVAIDS

For educational information on HIV infection or for more information on HIV surveillance in Georgia, visit DPH.ga.gov/epi/HIVAIDS

## Acknowledgements

Publication of this report was made possible with the contribution of the GDPH HAEP Core HIV surveillance staff and the health care facility staff assisting in the collection of enhanced perinatal surveillance data at centers providing care to HIV-infected pregnant women and their infants.

This report was prepared by the following staff, contractors and fellows working with the Georgia Department of Public Health: Darcie Lyn Everett, Denise Hughes, Jane Kelly, Rodriques Lambert, Mildred McGainey, and A. Eugene Pennisi.

Special recognition: Mildred McGainey for exemplary service as the Enhanced Perinatal Surveillance project coordinator for Georgia 2006-2011 and Darcie Lyn Everett for data analysis.



# Table of Contents

Mother-To-Child Transmission in Georgia	3
Technical Notes	4
Tabulation and Presentation of Data	4
Limitations	5
References	6
Tables	7
Figures 2	24
Appendix A - Georgia EPS Tertiary Care Facilities 3	33
Appendix B - Enhanced Perinatal Abstraction Form 3	34



### Background

During 2006-2011, the Georgia Department of Public Health (GDPH) was one of 15 sites funded by the Centers for Disease Control and Prevention (CDC) to conduct Enhanced HIV/AIDS Surveillance for Perinatal Prevention (also referred to as Enhanced Perinatal Surveillance or EPS) in Georgia. <sup>1</sup> EPS was designed to function as an extension to routine HIV/AIDS surveillance activities for the purposes of evaluating the prevention of perinatal HIV transmission and the effects of implementation of United States Preventive Services Task Force recommendations for screening and treatment of pregnant women and infants.<sup>2,3</sup> Georgia law O.C.G.A. § 31-17-4.2 mandates that every physician and health care provider who assumes responsibility for the prenatal care of a pregnant woman during gestation and at delivery shall be required to test for HIV except in cases where the woman refuses the testing.<sup>4</sup> Positive HIV confirmatory test results are reported to the GDPH HIV/AIDS Surveillance Section.

Perinatal surveillance differs in that HIV-exposed infants (those born to HIV-infected mothers) may or may not be infected with HIV. Antibody tests may be positive at birth regardless of the infant's true status due to transplacental transfer of maternal antibodies. Consequently, HIV-exposed infants identified through enhanced perinatal surveillance are followed by EPS staff up to 18 months of age or until their HIV-infection status is determined. It is the objective of EPS to follow the progress toward maximal reduction of perinatal HIV transmission.

Because of staffing shortages and re-structuring, mid-way in the funding period, EPS in Georgia was transitioned from a population-based to a facility-based surveillance system to focus efforts on seven tertiary care centers in Georgia with large maternal and pediatric HIV case loads (see Appendix A). During the last year of CDC funding for EPS (2011) work emphasis shifted from the ascertainment of new cases to the completion and close-out of previously reported cases (births during the years 2005-2010).

As a result, this report provides EPS data on a population based (2005-2006) and facility-based (2007-2010) sample of 695 HIV-infected pregnancies that resulted in 710 live births in Georgia during the years 2005-2010. The data are presented in aggregate for the years 2005-2010. The number of pregnancies investigated and sampling methodology changed during the surveillance period, thus precluding trend analysis. In 2011, the CDC published a surveillance report of EPS in 15 areas from 2005-2008<sup>1</sup> including information on 8,054 infants. Similar to the national report, this document is organized in three sections: (a) demographic, behavioral, and clinical information on HIV-infected pregnant women who gave birth; (b) demographic, behavioral, and clinical information on those women, by race/ethnicity; and (c) clinical information on infants born to these HIV-infected women. Figures 1-18 compare this Georgia sample of 710 HIV-exposed infants to the national sample of 8,054 infants. These data can be used to inform interventions to improve perinatal transmission prevention in Georgia. Missed opportunities to prevent perinatal infection have been noted in as many as 60% of HIV infected pregnancies nationally in the US<sup>5</sup>

## Highlights

- 1. The number of HIV infected pregnancies included in this report decreased over time; however, the data cannot be used for trend analysis.
- 2. EPS cases in this analysis are a sample of 695 HIV-infected pregnancies that resulted in 710 live births in Georgia in 2005-2010.
- 3. The majority (85%) of HIV-infected women reported to EPS were black, non-Hispanic. Hispanic/ Latinos and white, non-Hispanics constituted 6% and 7% of the total sample, respectively. Other races made up 2%, and unknown race, less than 1% of the sample.
- 4. The majority (58%) of HIV-infected pregnant women in Georgia had an unknown transmission category, supporting the concept that many women are unaware of their sexual partners' HIV status or high-risk behavior. Thirty-seven percent reported high-risk heterosexual contact. Only 2% had known exposure through injection drug use.
- 5. Most (90%) HIV-infected women in Georgia received some prenatal care. This proportion was comparable across races with 90% of black, 93% of Hispanic/Latino and 89% of white women receiving some prenatal care.
- 6. Almost two-thirds (64%) of HIV-infected pregnant women in Georgia were diagnosed before pregnancy, and 32% were diagnosed during pregnancy. Only 1% were found to be HIV infected at delivery and 1% after birth. Two percent had an unknown timing of their HIV diagnosis.
- 7. Most (81%) HIV-infected pregnant women in Georgia received prenatal antiretroviral therapy (ART) with 14% unknown; most (83%) received intrapartum ART with 12% unknown.
- 8. Prenatal ART use was documented for 80% of black, 83% of Hispanic/Latino and 85% of white HIV-infected pregnant women in Georgia. Prenatal ART use was unknown for 15%, 15% and 4% of black, Hispanic/Latino and white HIV-infected pregnancies, respectively.
- 9. Intrapartum ART delivery was documented for 84% of black, 75% of Hispanic/Latino and 89% of white HIV-infected pregnant women in Georgia. Intrapartum ART use was unknown for 12%, 2% and 4% of black, Hispanic/Latino and white HIV-infected pregnancies, respectively.
- 10. Most (87%) HIV-exposed infants received ART during the neonatal period with 12% unknown.
- 11. Assessment of neonatal ART use by race is limited by missing data: 11%, 27% and 11% were unknown for black, Hispanic/Latino and white HIV-exposed infants, respectively.
- 12. Similarly, data are missing for almost three fourths (74%) of HIV-exposed infants with regard to the proportion of HIV-exposed infants receiving *Pneumocystis* prophylaxis.
- Most (59%) of HIV-infected pregnant women in Georgia delivered via elective cesarean-section;
   31% had a vaginal delivery, 5% had a non-elective cesarean-section, 3% had a cesarean-section of unknown type and 3% had an unknown delivery type.
- 14. Almost two-thirds (62%) of HIV-infected pregnant women in Georgia had no documented use of illicit drugs during pregnancy with 26% unknown. Only 12% had a documented use of illicit drugs during pregnancy.
- 15. Most (59%) HIV-infected pregnant women in Georgia reported no tobacco or alcohol use during pregnancy with 26% unknown. Eleven percent reported tobacco use only, 2% alcohol use only, and 2% both tobacco and alcohol use.
- 16. Based on this sample of 695 HIV-infected pregnancies resulting in 710 live births in Georgia during 2005-2010, 2.5% (18/710) of HIV-exposed infants were diagnosed with mother-to-child HIV transmission; 317 infants (45%) were not infected with HIV and 375 (53%) remain in the indeterminate category. This is comparable to the US national rate of 2% mother-to-child transmission reported in the CDC EPS Surveillance Report.<sup>1</sup>
- 17. By race and ethnicity, the following percentages of HIV-exposed infants were delivered preterm: 26% of black infants, 20% of Hispanic/Latino infants, and 26% of white infants.
- 18. By race and ethnicity, the following percentages of HIV-exposed infants were low or very low birth weight: 24% of black infants, 12% of Hispanic/Latino infants, and 28% of white infants.

### **Mother-To-Child Transmission in Georgia**

Of the 18 pregnancies that resulted in mother-to-child (MTC) HIV transmission, 12 had received at least one prenatal visit (range 5-10), 4 had received no prenatal care, and the prenatal care status of 2 was unknown. Of the 12 women receiving prenatal care, all except two were diagnosed with HIV infection before or during pregnancy. One woman's diagnosis timing was unknown. One woman receiving prenatal care was HIV-negative early in pregnancy, was subsequently diagnosed with HIV after birth and faced extenuating social circumstances, including IV drug use and homelessness. Eight of ten women receiving prenatal care with a diagnosis of HIV prior to birth also received ART during pregnancy; one was not adherent to ART and one's prenatal ART status was unknown. Nine of ten received intrapartum ART; one woman delivered precipitously while in jail.

Of the six women with no or unknown prenatal care, three were known to be HIV infected before pregnancy, two were diagnosed at delivery, and one after delivery. One mother with no prenatal care did have CD4 and/or viral loads measured during pregnancy and received prenatal and intrapartum ART. Of the remaining three without prenatal care, one woman noted a lack of insurance coverage, one was born outside the US and had a significant language barrier, and one had a history of psychiatric disorder and substance abuse. One woman with unknown prenatal care had documented prenatal and intrapartum ART use.

Four women had Stage 3 disease or AIDS (CD4 < 200 or opportunistic infection) during pregnancy. Fifteen of eighteen pregnancies resulting in mother-to child transmission delivered via cesarean section. Eleven were preterm deliveries (< 37 weeks gestational age, range 27-36 weeks). All 18 infants received ART at birth. Eight infants were discharged on Pneumocystis prophylaxis with data missing for ten. Two infants had a diagnosis of AIDS.

Records indicate that most of these mothers faced challenging social circumstances, including sexually transmitted disease diagnosed during pregnancy (8), substance abuse during pregnancy (7), homelessness (1), psychiatric disorder (1), incarceration during pregnancy (1), referral to Georgia Division of Family and Children Services (1) and language barrier (1).

## **Technical Notes**

This surveillance report describes the data collected in Georgia though the CDC-funded Enhanced Perinatal Surveillance (EPS) project. Data were collected using both the HIV Case Report Form and a supplemental EPS data abstraction form (see Appendix B).

Mother-infant pairs were identified through several means: pediatric HIV surveillance, birth registry match, hospital discharge summaries, and personal communication with case managers and personnel at tertiary medical facilities and pediatric clinics. Linkage with the enhanced HIV/AIDS Reporting System (eHARS) and the birth registry for the birth years 2005-2010 assisted with identifying possible mother-infant pairs.

Using the EPS abstraction form, we collected information on the mother's demographics, prenatal care, sexually transmitted disease screenings, HIV testing history, receipt of antiretroviral therapy (ART), alcohol, tobacco and substance abuse, type of delivery, and infant's clinical information, including whether the infant was prescribed ART and Pneumocystis prophylaxis. Methods used to collect these data required linkage of mother-infant pairs and review of records of both mother and infant. These records included prenatal care records, maternal HIV clinical records, labor and delivery records, pediatric birth records, pediatric clinic records, birth certificates, death certificates and health department records with matching to eHARS. Follow up of the infants' HIV status was conducted until the infant's HIV status was ascertained or indeterminate. Indeterminate cases include cases with missing or unknown HIV status as of linkage with eHARS in May 2013.

For the years 2005-2006, Georgia performed population-based data collection to include all HIVexposed infants born within the state of Georgia. For 2007-2010, Georgia performed facility-based data collection from seven facilities identified as serving large numbers of HIV-infected women (e.g., delivery hospitals) and HIV-exposed children.

## **Tabulation and Presentation of Data**

Data in this report are provisional. All data are aggregated for Georgia 2005-2010 and for the national US sample of 15 jurisdictions 2005-2008. The race/ethnicity categories used in this report are the categories used following the implementation of the Office of Management and Budget (OMB) Statistical Policy Directive 15<sup>6</sup> and are the same categories used by the CDC. Because of the small numbers of HIV-infected pregnancies among American Indian/Alaska Native, Asian and Native Hawaiian/Other Pacific Islander women in Georgia, data are depicted only for black, Hispanic/Latino and white pregnancies with all other race and ethnicity groups aggregated as "Other".

In this analysis, transmission categories for HIV-infected women use the CDC-assigned definition, and are hierarchical. If a woman is reported as having more than one possible route of transmission, she is counted only once in the transmission category listed first in the hierarchy. The heterosexual contact category refers specifically to women who have reported heterosexual contact with a man known to be infected with HIV or who is known to be at increased risk for acquiring HIV infection (e.g. via injection drug use or male to male sexual contact).

In this report, missing data are indicated as unknown. Missing data may result from incomplete medical records, patients who are lost to follow-up, or the unavailability of records. Children younger than 18 months born to an HIV-infected mother are classified as infected or not infected only if virologic or antibody testing confirms this status during specified periods. Children for whom such laboratory results are missing, or which were not performed during the specified period to confirm or rule out infection, are classified as indeterminate.<sup>7</sup> As more than half (53%) of infants are classified in this report as having indeterminate HIV status, caution must be used in interpreting perinatal HIV transmission rates. It is presumed that many, if not all, of these cases are not infected with HIV, but their status is categorized as indeterminate because the criteria for classification as not infected has not been met. CDC funding for EPS in Georgia ended in December 2011. The GDPH HIV/AIDS Surveillance program assumes ongoing responsibility for surveillance of adult and pediatric HIV infection, but is unable to complete the additional detailed medical records abstractions performed through EPS.

#### Limitations

This report of EPS in Georgia 2005-2010 and comparison to the national sample 2005-2008 is subject to several limitations:

- 1. The methodology changed mid-point from population-based to facility-based, precluding trend analysis.
- 2. The facility-based sample may not accurately reflect HIV perinatal care for all of Georgia.
- 3. The large proportion of unknown values for some variables limits comparisons within category and to the national sample.
- 4. The large proportion of indeterminate HIV status for HIV-exposed infants limits estimation of mother-to-child (MTC) transmission in Georgia using this sample. However, as all HIV confirmatory laboratory tests are reported to Georgia HIV/AIDS Surveillance, it is unlikely that infants included in this sample (born 2005-2010) with HIV positive tests would have not been reported by 2013.
- 5. Women who are HIV-infected before pregnancy are usually not reported again to surveillance in Georgia upon becoming pregnant, limiting identification of the denominator of all HIV- infected pregnancies in Georgia, and calculation of MTC transmission in Georgia.
- 6. The definition of heterosexual contact as sexual contact with a man known to be HIV infected or in a high-risk transmission category (e.g., injection drug use or men who have sex with men) contributes to the high proportion of women with an unknown transmission category
- 7. All data presented in this report are provisional.

#### References

- 1. Centers for Disease Control and Prevention. Enhanced Perinatal Surveillance -15 areas, 2005-2008. HIV Supplemental Surveillance Report 2011;16(No.2) http://www.cdc.gov/hiv/topics/surveillance/ resources/reports/. Published April 2011. Accessed March 24, 2013.
- 2. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf.
- 3. CDC. Revised recommendations for HIV testing of adults, adolescents and pregnant women in health care settings. MMWR 2006; 55(RR-14):1-17.
- 4. "Georgia HIV Pregnancy Screening Act of 2007." 2010 Georgia Code TITLE 31 HEALTH CHAPTER 17 - CONTROL OF VENEREAL DISEASE § 31-17-4.2 - HIV Pregnancy Screening http://statutes.laws.com/georgia/title-31/chapter-17/31-17-4-2 Accessed April 6, 2013.
- 5. Whitmore SK, Patel-Larson A, Espinoza L, et.al. Missed opportunities to prevent perinatal human immunodeficiency virus transmission in 15 jurisdictions in the United States during 2005-2008. Women Health 2010 Jul;50(5):414-25.
- 6. Office of Management and Budget. Revisions to the standards for the classification of federal data on race and ethnicity. *Federal Register* 1997;62:58781-58790. http://www.whitehouse.gov/omb/fedreg\_1997standards Accessed April 7, 2013.
- 7. CDC. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years United States, 2008. MMWR 2008;57(RR-10);1-12.

### **Tables**

selected charac	lensuics		=1, 2005-2	2010 0									6	-1 - 4 <sup>2</sup>
						ar of inf		-					-	lative
		05		06		07		08		009		010		otal
	No.	%ª	No.	% <sup>a</sup>	No.	% <sup>a</sup>	No.	% <sup>a</sup>	No.	% <sup>a</sup>	No.	% a	No.	% <sup>b</sup>
Age at delivery (yr)	1													
13-19	7	5	5	3	12	12	12	11	7	6	5	7	48	7
20-24	34	23	46	31	29	28	31	29	33	28	26	38	199	29
25-34	91	60	72	49	46	44	48	44	59	51	31	45	347	50
≥ 35	19	13	24	16	17	16	17	16	17	15	7	10	101	15
Race/ethnicity														
Black/African American	127	84	127	86	84	81	90	83	104	90	62	90	594	85
Hispanic/Latino	11	7	9	6	9	9	4	4	3	3	4	6	40	6
White	9	6	10	7	9	9	9	8	6	5	3	4	46	7
Other <sup>c</sup>	4	3	0	0	2	2	4	4	2	2	0	0	12	2
Unknown	0	0	1	1	0	0	1	1	1	1	0	0	3	<1
Transmission category	,													
Injection drug use	3	2	7	5	1	1	1	1	4	3	1	1	17	2
Heterosexual contact <sup>d</sup>	73	48	39	27	46	44	37	34	41	35	18	26	254	37
Other <sup>e</sup>	3	2	1	1	6	6	2	2	5	4	3	4	20	3
Unknown	72	48	100	68	51	49	68	63	66	57	47	68	404	58
Marital status														
Single	86	57	107	73	73	70	70	65	92	79	57	83	485	70
Married	37	25	34	23	20	19	32	30	18	16	8	12	149	21
Separated	1	1	1	1	3	3	1	1	3	3	1	1	10	1
Divorced	3	2	4	3	2	2	1	1	2	2	1	1	13	2
Widowed	3	2	1	1	0	0	0	0	0	0	1	1	5	1
Unknown	21	14	0	0	6	6	4	4	1	1	1	1	33	5
Mother's country of bi	rth													
United States	92	61	107	73	87	84	87	81	99	85	57	83	529	76
Other	9	6	28	19	11	11	13	12	13	11	11	16	85	12
Unknown	50	33	12	8	6	6	8	7	4	3	1	1	81	12
Total	151		147		104		108	ĺ	116		69		695	

Note: Because of rounding, column percentages may not total 100%.

<sup>a</sup> Percentages represent proportions of the total number of HIV-infected pregnancies for a given birth year.

<sup>b</sup> Percentages represent proportions of the total number of HIV-infected pregnancies for all six birth years.

<sup>c</sup> Includes Asian, American Indian/ Alaskan Native, Native Hawaiian/ Other Pacific Islander, multiple races and other races.

 $^{\rm d}$  Heterosexual contact with a person known to have, or be at high risk for, HIV.

<sup>e</sup> Includes blood transfusion and perinatal exposure.

Table 2. Prenatal care of	HIV-infe	cted wo	omen, by	year of i	nfant's k	oirth, 20	05-2010	– Georg	ia					
					Ye	ar of inf	ant's bi	rth					Cumu	ılative
	20	05	20	06	20	07	20	08	20	09	20	010	То	tal
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Prenatal care <sup>a</sup>														
Yes														
No	9	6	7	5	0	0	4	4	4	3	4	6	28	4
Unknown	25	17	11	7	2	2	2	2	0	0	0	0	40	6
Total	151		147		104		108		116		69		695	

Note: Because of rounding, column percentages may not total 100%.

<sup>a</sup> Includes only women who had documentation of prenatal care in their records. Prenatal care is the regular health care women should receive during pregnancy from an obstetrician or midwife.

Table 3. Timing of HIV te	esting di	agnosis	of HIV-	infected w	omen,	by year o	of infant	's birth, i	2005-20	10 – Geoi	rgia				
					Ye	ar of inf	ant's bi	rth					Cumu	lative	
	20	05	2	006	20	07	20	08	20	09	20	010	То	tal	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	
Timing of mother's HIV	/ test														
Before pregnancy	92	61													
During pregnancy	52	34													
At delivery	1	1	2	1	0	0	1	1	1	1	1	1	6	1	
After birth	1	1	1	1	1	1	0	0	1	1	0	0	4	1	
Unknown	5	3	3	2	1	1	3	3	2	2	1	1	15	2	
Total	151		147		104		108		116		69		695		

Note: Because of rounding, column percentages may not total 100%.

Receipt of antiretroviral					Ye	ar of inf	ant's bi	rth					Cumu	lative
therapy	20	05	20	06	20	07	20	08	20	09	20	)10	То	tal
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Prenatal period – HIV-infe	cted wo	menª							·					
Yes	115	76	107	73	89	86	84	78	103	89	65	94	563	81
No	9	6	10	7	2	2	3	3	6	5	3	4	33	5
Unknown	27	18	30	20	13	13	21	19	7	6	1	1	99	14
Total	151		147		104		108		116		69		695	
Intrapartum period – HIV-	infected	l women	a											
Yes	109	72	116	79	97	93	87	81	107	92	64	93	580	83
No	8	5	8	5	1	1	9	8	5	4	2	3	33	5
Unknown	34	23	23	16	6	6	12	11	4	3	3	4	82	12
Total	151		147		104		108		116		69		695	
Neonatal period – HIV-exp	posed in	fants⁵												
Yes	141	92	123	82	96	88	95	86	97	83	64	93	616	87
No	0	0	1	1	0	0	5	5	3	3	0	0	9	1
Unknown	13	8	26	17	13	12	11	10	17	15	5	7	85	12
Total	154		150		109		111		117		69		710	

Note: Because of rounding, column percentages may not total 100%.

<sup>a</sup> Prenatal and intrapartum antiretroviral therapy are reported for each pregnancy. The numbers of women receiving antiretroviral therapy prenatally and intrapartum are not mutually exclusive.

<sup>b</sup> Neonatal antiretroviral therapy is reported for each HIV-exposed infant.

Table 5. Method of deliver	y for HIV	-infecte	d wome	n, by yea	r of infa	nt's birth	n, 2005-2	2010 – G	eorgia					
					Ye	ar of inf	ant's bi	rth					Cumu	Ilative
	20	05	20	06	20	07	20	08	20	09	20	010	То	tal
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Method of delivery														
Vaginal	50	33	39	27	28	27	32	30	38	33	28	41	215	31
Cesarean														
Elective <sup>a</sup>	92	61	92	63	68	65	62	57	71	61	24	35	409	59
Non-elective	4	3	7	5	3	3	4	4	5	4	9	13	32	5
Type of decision unknown	0	0	1	1	3	3	6	6	1	1	8	12	19	3
Unknown	5	3	8	5	2	2	4	4	1	1	0	0	20	3
Total	151		147		104		108		116		69		695	

Note: Because of rounding, column percentages may not total 100%.

<sup>a</sup> Refers to a cesarean section that is performed before the membranes rupture and before labor begins. However, a planned cesarean section that was performed ahead of schedule because of unexpected circumstances was considered elective.

Table 6. Substance use a	and toxio	cology s	creening	of HIV-ii	nfected	women	during p	oregnan	cy, by ye	ar of infa	nt's birt	h, 2005-	2010 – G	ieorgia
					Ye	ar of inf	ant's bi	rth					Cumu	lative
	20	05	20	06	20	07	20	08	20	09	20	010	То	tal
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Illicit drug use <sup>a</sup>														
Yes	19	13	21	14	6	6	12	11	13	11	10	14	81	12
No	76	50	80	54	78	75	65	60	82	71	51	74	432	62
Unknown	56	37	46	31	20	19	31	29	21	18	8	12	182	26
Alcohol/tobacco use <sup>b</sup>														
Alcohol	1	1	3	2	1	1	3	3	3	3	2	3	13	2
Tobacco	10	7	22	15	8	8	11	10	15	13	11	16	77	11
Alcohol and tobacco	2	1	5	3	0	0	2	2	4	3	0	0	13	2
Neither	82	54	71	48	75	72	61	56	73	63	48	70	410	59
Unknown	56	37	46	31	20	19	31	29	21	18	8	12	182	26
Toxicology screening <sup>c</sup>														
Positive result	16	11	18	12	4	4	10	9	15	13	6	9	69	10
Negative result	40	26	54	37	34	33	31	29	52	45	37	54	248	36
Not done	4	3	1	1	3	3	2	2	2	2	0	0	12	2
Unknown	91	60	74	50	63	61	65	60	47	41	26	38	366	53
Total	151		147		104		108		116		69		695	

Note: Because of rounding, column percentages may not total 100%.

<sup>a</sup> Included only if noted in medical or social work records during pregnancy: amphetamines, barbiturates, benzodiazepines, cocaine, crack, hallucinogens, heroin, marijuana, methadone, methamphetamines, opiates, or other drugs.

<sup>b</sup> Included only if noted in the medical or social work records during pregnancy.

<sup>c</sup> Conducted during pregnancy. If more than one toxicology screening was done and any result was positive, the screening result was considered positive.

					Va	ar of inf	ant's hi	rth					Cumu	lative
														tal
	20	05	20	06	20	07	20	08	20	09	20	010	10	
Screening <sup>®</sup>	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Group B Streptococcus														
Yes	75	50	95	65	68	65	65	60	76	66	49	71	428	62
No	7	5	6	4	0	0	3	3	1	1	2	3	19	3
Unknown	69	46	46	31	36	35	40	37	39	34	18	26	248	36
Hepatitis B					0			•						
Yes	118	78	135	92	89	86	87	81	100	86	64	93	593	85
No	1	1	0	0	0	0	0	0	0	0	0	0	1	<1
Unknown	32	21	12	8	15	14	21	19	16	14	5	7	101	15
Rubella	<u>.</u>				°			°			·			
Yes	119	79	136	93	88	85	86	80	98	84	61	88	588	85
No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Unknown	32	21	11	7	16	15	22	20	18	16	8	12	107	15
Syphilis														
Yes	111	74	131	89	82	79	80	74	96	83	67	97	567	82
No	0	0	0	0	0	0	0	0	1	1	0	0	1	<1
Unknown	40	26	16	11	22	21	28	26	19	16	2	3	127	18
Total	151		147		104		108		116		69		695	

Note: Because of rounding, column percentages may not total 100%.

<sup>a</sup> Screening performed during pregnancy. Each woman is represented four times, once for each condition.

					Ye	ar of inf	ant's bi	rth					Cumu	ılative
	20	05	20	06	20	07	20	08	20	09	20	010	То	tal
Diagnosis	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Sexually transmitted d	iseaseª													
Yes	35	23	47	32	39	38	33	31	40	34	22	32	216	31
No or unknown <sup>b</sup>	116	77	100	68	65	63	75	69	76	66	47	68	479	69
Selected conditionc														
Yes	19	13	39	27	26	25	21	19	20	17	16	23	141	20
No or unknown <sup>d</sup>	132	87	108	73	78	75	87	81	96	83	53	77	554	80
Total	151		147		104		108		116		69		695	

Note: Because of rounding, column percentages may not total 100%.

<sup>a</sup> Includes presumptive or definitive diagnosis during pregnancy of the following sexually transmitted diseases: chlamydia, genital herpes (primary herpes and active lesions), gonorrhea, hepatitis B, syphilis, and trichomonas.

<sup>b</sup> There were no cases where trichomonas diagnosis was definitively negative. However, women in the "No or unknown" category did not have a known positive diagnosis of the above sexually transmitted infections.

<sup>c</sup> Includes presumptive or definitive diagnosis during pregnancy of the following conditions: bacterial vaginosis, group B Streptococcus, hepatitis C, or pelvic inflammatory disease.

<sup>d</sup> There were no cases where bacterial vaginosis diagnosis was definitively negative. However, women in the "No or unknown" category did not have a known positive diagnosis of the selected conditions.

#### Georgia Department of Public Health

Table 9. Prenatal care of	HIV-infe	cted wo	men, by	race/eth	nicity a	nd year	of infan	t's birth	, 2005-20	010 – Geo	orgia			
					Yea	ar of in	fant's bi	irth					Cumu	lative
	20	05	20	06	20	07	20	08	20	09	20	010	То	tal
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
				BI	ack/Afı	rican A	mericar	n						
Prenatal care <sup>a</sup>								0	0					
Yes	99	78	112	88	82	98	85	94	100	96	58	94	536	90
No	6	5	7	6	0	0	3	3	4	4	4	6	24	4
Unknown	22	17	8	6	2	2	2	2	0	0	0	0	34	6
Total	127		127		84		90		104		62		594	
					Hispa	anic/La	tino						·	
Prenatal care <sup>a</sup>						•	•	1	1					
Yes	10	91	7	78	9	100	4	100	3	100	4	100	37	93
No	1	9	0	0	0	0	0	0	0	0	0	0	1	3
Unknown	0	0	2	22	0	0	0	0	0	0	0	0	2	5
Total	11		9		9		4		3		4		40	
						White								
Prenatal care <sup>a</sup>														
Yes	5	56	10	100	9	100	8	89	6	100	3	100	41	89
No	2	22	0	0	0	0	1	11	0	0	0	0	3	7
Unknown	2	22	0	0	0	0	0	0	0	0	0	0	2	4
Total	9		10		9		9		6		3		46	

Note: Because of rounding, column percentages may not total 100%. Other and unknown races are excluded due to small numbers.

See Table 2 for cumulative totals of all races.

<sup>a</sup> Includes only women who had documentation of prenatal care in their records. Prenatal care is the regular health care women should receive during pregnancy from an obstetrician or midwife.



Table 10. Timing of HIV	/ testing d	liagnosi	s of HIV-i	nfected	women,	by race/	ethnicit	y and ye	ear of inf	ant's birt	h, 2005	-2010 – 0	Georgia	
					Ye	ar of inf	ant's bi	rth					Cumu	lative
Timing of mother's	20	05	20	06	20	07	20	08	20	09	20	010	То	tal
HIV test	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
				В	lack/Af	rican Ar	nerican							
Before pregnancy	75	59	73	57	58	69	62	69	68	65	40	65	376	63
During pregnancy	47	37	49	39	24	29	26	29	32	31	21	34	199	34
At delivery	0	0	2	2	0	0	0	0	1	1	1	2	4	1
After birth	0	0	0	0	1	1	0	0	1	1	0	0	2	<1
Unknown	5	4	3	2	1	1	2	2	2	2	0	0	13	2
Total	127		127		84		90		104		62		594	
					Hisp	anic/Lat	tino							
Before pregnancy	7	64	4	44	8	89	2	50	3	100	1	25	25	63
During pregnancy	3	27	5	56	1	11	2	50	0	0	2	50	13	33
At delivery	1	9	0	0	0	0	0	0	0	0	0	0	1	3
After birth	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Unknown	0	0	0	0	0	0	0	0	0	0	1	25	1	3
Total	11		9		9		4		3		4		40	
						White								
Before pregnancy	7	78	6	60	8	89	5	56	5	83	3	100	34	74
During pregnancy	1	11	3	30	1	11	2	22	1	17	0	0	8	17
At delivery	0	0	0	0	0	0	1	11	0	0	0	0	1	2
After birth	1	11	1	10	0	0	0	0	0	0	0	0	2	4
Unknown	0	0	0	0	0	0	1	11	0	0	0	0	1	2
Total	9		10		9		9		6		3		46	

Note: Because of rounding, column percentages may not total 100%. Other and unknown races are excluded due to small numbers. See Table 3 for cumulative totals of all races.

Table 11. Receipt of anti race/ethnicity,							V-expos	ed infan	ts, by tin	ning of re	eceipt o	f therapy	Ι,	
						ar of inf	fant's bi	rth					Cumu	lative
Receipt of antiretroviral	20	05	20	06	20	007	20	08	20	)09	20	010	То	tal
therapy	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
				В	lack/Af	rican Aı	nerican							
Prenatal period – HIV-infe	ected wo	men												
Yes	96	76	92	72	71	85	70	78	91	88	58	94	478	80
No	6	5	9	7	2	2	1	1	6	6	3	5	27	5
Unknown	25	20	26	20	11	13	19	21	7	7	1	2	89	15
Total	127		127		84		90		104		62		594	
Intrapartum period – HIV	-infected	l women												
Yes	91	72	102	80	78	93	73	81	95	91	57	92	496	84
No	6	5	6	5	1	1	7	8	5	5	2	3	27	5
Unknown	30	24	19	15	5	6	10	11	4	4	3	5	71	12
Total	127		127		84		90		104		62		594	
Neonatal period – HIV-ex	posed in	fants												
Yes	122	94	109	84	79	90	80	86	86	82	58	94	534	88
No	0	0	1	1	0	0	4	4	3	3	0	0	8	1
Unknown	8	6	20	15	9	10	9	10	16	15	4	6	66	11
Total	130		130		88		93		105		62		608	
	•	·	°		Hisp	anic/La	tino				<u> </u>	<u> </u>		
Prenatal period – HIV-infe	ected wo	men												
Yes	9	82	6	67	8	89	3	75	3	100	4	100	33	83
No	1	9	0	0	0	0	0	0	0	0	0	0	1	3
Unknown	1	9	3	33	1	11	1	25	0	0	0	0	6	15
Total	11		9		9		4		3		4		40	
Intrapartum period – HIV	-infected	l women	° 											
Yes	8	73	4	44	8	89	3	75	3	100	4	100	30	75
No	1	9	1	11	0	0	0	0	0	0	0	0	2	5
Unknown	2	18	4	44	1	11	1	25	0	0	0	0	8	20
Total	11		9		9		4		3		4		40	
Neonatal period – HIV-ex	posed in	fants												
Yes	8	73	5	56	7	70	3	75	3	100	4	100	30	73
No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Unknown	3	27	4	44	3	30	1	25	0	0	0	0	11	27
Total	11		9		10		4		3		4		41	

Table 11. Receipt of antii race/ethnicity,		-					-	ed infan	ts, by tin	ning of re	eceipt of	therapy	Ι,	
					Ye	ar of inf	ant's bi	rth					Cumu	ulative
Receipt of antiretroviral	20	05	20	06	20	07	20	08	20	009	20	010	То	tal
therapy	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
						White								
Prenatal period – HIV-infe	cted wo	menª												
Yes	7	78	8	80	8	89	7	78	6	100	3	100	39	85
No	2	22	1	10	0	0	2	22	0	0	0	0	5	11
Unknown	0	0	1	10	1	11	0	0	0	0	0	0	2	4
Total	9		10		9		9		6		3		46	
Intrapartum period – HIV-	infected	women	а											
Yes	7	78	9	90	9	100	7	78	6	100	3	100	41	89
No	1	11	1	10	0	0	1	11	0	0	0	0	3	7
Unknown	1	11	0	0	0	0	1	11	0	0	0	0	2	4
Total	9		10		9		9		6		3		46	
Neonatal period – HIV-exp	oosed in	fants⁵												
Yes	8	89	9	90	9	100	8	89	5	83	2	67	41	89
No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Unknown	1	11	1	10	0	0	1	11	1	17	1	33	5	11
Total	9		10		9		9		6		3		46	

Table 11 Descint of antivotyoutral theorem by UIV infected women and UIV expected infects, by timing of receint of theorem.

Note: Because of rounding, column percentages may not total 100%. Other and unknown races are excluded due to small numbers. See Table 4 for cumulative totals of all races.

<sup>a</sup> Prenatal and intrapartum antiretroviral therapy are reported for each pregnancy. The numbers of women receiving antiretroviral therapy prenatally and intrapartum are not mutually exclusive.

<sup>b</sup> Neonatal antiretroviral therapy is reported for each HIV-exposed infant.



					Ye	ar of inf	ant's bi	rth					Cumu	Ilative
	20	05	20	06	20	07	20	08	20	09	20	010	То	tal
Method of delivery	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
				B	lack/Af	rican Ar	nerican	 I						
Vaginal	41	32	30	24	18	21	25	28	34	33	25	40	173	29
Cesarean														
Elective <sup>a</sup>	78	61	84	66	60	71	52	58	64	62	22	35	360	61
Non-elective	4	3	5	4	3	4	4	4	4	4	8	13	28	5
Type of decision unknown	0	0	1	1	1	1	6	7	1	1	7	11	16	3
Unknown	4	3	7	6	2	2	3	3	1	1	0	0	17	3
Total	127		127		84		90		104		62		594	
					Hisp	anic/Lat	tino							
Vaginal	5	45	3	33	4	44	1	25	1	33	2	50	16	40
Cesarean														
Elective <sup>a</sup>	6	55	4	44	4	44	2	50	2	67	1	25	19	48
Non-elective	0	0	1	11	0	0	0	0	0	0	0	0	1	3
Type of decision unknown	0	0	0	0	1	11	0	0	0	0	1	25	2	5
Unknown	0	0	1	11	0	0	1	25	0	0	0	0	2	5
Total	11		9		9		4		3		4		40	
	<u> </u>					White								
Vaginal	2	22	6	60	4	44	3	33	1	17	1	33	17	37
Cesarean														
Elective <sup>a</sup>	6	67	4	40	4	44	6	67	4	67	1	33	25	54
Non-elective	0	0	0	0	0	0	0	0	1	17	1	33	2	4
Type of decision unknown	0	0	0	0	1	11	0	0	0	0	0	0	1	2
Unknown	1	11	0	0	0	0	0	0	0	0	0	0	1	2
Total	9		10		9		9		6		3		46	

Note: Because of rounding, column percentages may not total 100%. Other and unknown races are excluded due to small numbers. See Table 5 for cumulative totals of all races. <sup>a</sup> Refers to a cesarean section that is performed before the membranes rupture and before labor begins. However, a planned cesarean section that was performed ahead of schedule because of unexpected circumstances was considered elective.

Table 13. Substance use 2005-2010 – G		leology	Screenin	gorniv	meetee	women	aanng	pregnai	icy, by ic	ice, cum	city une	i year or	innunit 5 i	on en,
					Ye	ar of inf	ant's bi	rth					Cumu	lative
	20	05	20	06	20	07	20	08	20	)09	20	010	То	tal
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
					Africa	an Amer	rican							
Illicit drug use <sup>a</sup>														
Yes	16	13	18	14	5	6	8	9	13	13	10	16	70	12
No	63	50	71	56	62	74	55	61	71	68	45	73	367	62
Unknown	48	38	38	30	17	20	27	30	20	19	7	11	157	26
Alcohol/tobacco use <sup>b</sup>														
Alcohol	1	1	3	2	1	1	2	2	3	3	2	3	12	2
Tobacco	9	7	18	14	5	6	9	10	11	11	8	13	60	10
Alcohol and tobacco	2	2	4	3	0	0	0	0	3	3	0	0	9	2
Neither	67	53	64	50	61	73	52	58	67	64	45	73	356	60
Unknown	48	38	38	30	17	20	27	30	20	19	7	11	157	26
Toxicology screening <sup>c</sup>			0.	0	0	0			0					
Positive result	14	11	16	13	3	4	8	9	14	13	6	10	61	10
Negative result	38	30	43	34	31	37	27	30	48	46	34	55	221	37
Not done	4	3	1	1	0	0	2	2	2	2	0	0	9	2
Unknown	71	56	67	53	50	60	53	59	40	38	22	35	303	51
Total	127		127		84		90		104		62		594	
					Hisp	anic/Lat	tino							
Illicit drug use <sup>a</sup>														
Yes	0	0	0	0	0	0	0	0	0	0	0	0	0	0
No	8	73	5	56	8	89	4	100	3	100	3	75	31	78
Unknown	3	27	4	44	1	11	0	0	0	0	1	25	9	23
Alcohol/tobacco use <sup>b</sup>														
Alcohol	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Tobacco	1	9	1	11	0	0	0	0	1	33	0	0	3	8
Alcohol and tobacco	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Neither	7	64	4	44	8	89	4	100	2	67	3	75	28	70
Unknown	3	27	4	44	1	11	0	0	0	0	1	25	9	23
Toxicology screening <sup>c</sup>														
Positive result	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Negative result	1	9	5	56	2	22	1	25	1	33	3	75	13	33
Not done	0	0	0	0	2	22	0	0	0	0	0	0	2	5
Unknown	10	91	4	44	5	56	3	75	2	67	1	25	25	63
Total	11		9		9		4		3		4		40	

Georgia Department of Public Health

					Ye	ar of inf	ant's bi	rth					Cumu	ılative
	20	05	20	06	20	07	20	08	20	09	20	010	То	tal
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
						White								
Illicit drug use <sup>a</sup>														
Yes	2	22	3	30	1	11	3	33	0	0	0	0	9	20
No	3	33	4	40	6	67	4	44	5	83	3	100	25	54
Unknown	4	44	3	30	2	22	2	22	1	17	0	0	12	26
Alcohol/tobacco use <sup>b</sup>														
Alcohol	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Tobacco	0	0	3	30	3	33	2	22	1	17	3	100	12	26
Alcohol and tobacco	0	0	1	10	0	0	2	22	1	17	0	0	4	9
Neither	5	56	3	30	4	44	3	33	3	50	0	0	18	39
Unknown	4	44	3	30	2	22	2	22	1	17	0	0	12	26
Toxicology screening <sup>c</sup>														
Positive result	1	11	2	20	1	11	2	22	1	17	0	0	7	15
Negative result	1	11	5	50	1	11	1	11	1	17	0	0	9	20
Not done	0	0	0	0	1	11	0	0	0	0	0	0	1	2
Unknown	7	78	3	30	6	67	6	67	4	67	3	100	29	63
Total	9		10		9		9		6		3		46	

Note: Because of rounding, column percentages may not total 100%. Other and unknown races are excluded due to small numbers. See Table 6 for cumulative totals of all races.

<sup>a</sup> Included only if noted in medical or social work records during pregnancy: amphetamines, barbiturates, benzodiazepines, cocaine, crack, hallucinogens, heroin, marijuana, methadone, methamphetamines, opiates, or other drugs.

<sup>b</sup> Included only if noted in the medical or social work records during pregnancy.

<sup>c</sup> Conducted during pregnancy. If more than one toxicology screening was done and any result was positive, the screening result was considered positive.

Table 14. Type of birth, b	oy year o	of infant'	s birth, 2	005-201	0 – Geoi	rgia								
					Ye	ar of inf	ant's bi	rth					Cumu	lative
	20	05	20	06	20	07	20	08	20	09	20	010	То	tal
	No.	% <sup>a</sup> No.         % <sup>a</sup> No.         % <sup>a</sup> No.         % <sup>a</sup> No.         % <sup>a</sup>												<b>%</b> <sup>b</sup>
Type of birth														
Single	147	95	144	96	98	90	104	94	115	98	68	99	676	95
Twin	6	4	6	4	10	9	6	5	2	2	0	0	30	4
Triplet or greater	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Unknown	1	1	0	0	1	1	1	1	0	0	1	1	4	1
Total	154		150		109		111		117		69		710	

Note: Because of rounding, column percentages may not total 100%. Numbers are reported for total number of HIV-exposed infants.

<sup>a</sup> Percentages represent proportions of the total number of HIV-exposed infants for a given birth year.

<sup>b</sup> Percentages represent proportions of the total number of HIV-exposed infants for all six birth years.

Table 15. Number and p by year of infa					ophylaxi	s agains	t Pneum	ocystis	jiroveci p	oneumon	ia durir	ng the fir	st year o	of life,
					Ye	ar of inf	ant's bi	rth					Cumu	lative
	20	05	20	06	20	07	20	08	20	09	20	010	То	tal
	No.         %         No.         %         No.         %         No.         %         No.         %           ived                 %          %													
Prophylaxis received														
Yes	36	23	28	19	23	21	22	20	16	14	10	14	135	19
No	4	3	8	5	13	12	5	5	6	5	17	25	53	7
Unknown	114	74	114	76	73	67	84	76	95	81	42	61	522	74
Total	154		150		109		111		117		69		710	

Note: Because of rounding, column percentages may not total 100%. Numbers and percentages are reported for total number of HIV-exposed infants.

Table 16. Number and percentage of infants infected with HIV through mother-to-child transmission, by year of infant's birth, 2005-2010 – Georgia

					Ye	ar of inf	ant's bi	rth					Cumu	lative
	20	05	20	06	20	07	20	08	20	09	20	010	То	tal
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
HIV status														
Infected	3	2	4	3	4	4	3	3	2	2	2	3	18	3
Not infected	98	64	71	47	47	43	38	34	33	28	30	43	317	45
Indeterminate <sup>a</sup>	53	34	75	50	58	53	70	63	82	70	37	54	375	53
Total	154		150		109		111		117		69		710	

Note: Because of rounding, column percentages may not total 100%. Numbers and percentages are reported for total number of HIV-exposed infants.

<sup>a</sup> Includes cases with missing infant's HIV status. Indeterminate status determined as of May 2013.

					Ye	ar of inf	ant's bi	rth					Cumu	lative
	20	05	20	06	20	007	20	08	20	09	20	010	То	otal
HIV status	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
				В	lack/Af	rican Ar	nerican							
Infected	3	2	3	2	4	5	1	1	2	2	2	3	15	2
Not infected	85	65	63	48	39	44	34	37	29	28	26	42	276	45
Indeterminate <sup>a</sup>	42	32	64	49	45	51	58	62	74	70	34	55	317	52
Total	130		130		88		93		105		62		608	
					Hisp	anic/Lat	tino							
Infected	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Not infected	7	64	3	33	5	50	1	25	2	67	3	75	21	51
Indeterminate <sup>a</sup>	4	36	6	67	5	50	3	75	1	33	1	25	20	49
Total	11		9		10		4		3		4		41	
	- -				• •	White			·	<u> </u>				
Infected	0	0	1	10	0	0	2	22	0	0	0	0	3	7
Not infected	5	56	5	50	2	22	1	11	1	17	1	33	15	33
Indeterminate <sup>a</sup>	4	44	4	40	7	78	6	67	5	83	2	67	28	61
Total	9		10		9		9		6		3		46	

Note: Because of rounding, column percentages may not total 100%. Numbers and percentages are reported for total number of HIV-exposed infants. Other and unknown races are excluded due to small numbers. See Table 16 for cumulative totals of all races.

<sup>a</sup> Includes cases with missing infant's HIV status. Indeterminate status determined as of May 2013.

#### Georgia Department of Public Health

					Ye	ar of inf	ant's bi	rth					Cumu	lative
	20	05	20	06	20	07	20	08	20	09	20	010	То	tal
Birth weight (gms)	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
				В	lack/Af	rican Ar	nerican							
Very low birth weight <sup>a</sup>	3	2	7	5	4	5	2	2	7	7	1	2	24	4
Low birth weight <sup>b</sup>	29	22	29	22	15	17	21	23	19	18	9	15	122	20
Normal <sup>c</sup>	96	74	93	72	68	77	68	73	79	75	51	82	455	75
Unknown	2	2	1	1	1	1	2	2	0	0	1	2	7	1
Total	130		130		88		93		105		62		609	
					Hisp	anic/Lat	tino							
Very low birth weight <sup>a</sup>	0	0	0	0	1	10	0	0	0	0	0	0	1	2
Low birth weight <sup>b</sup>	1	9	2	22	1	10	0	0	0	0	0	0	4	10
Normal <sup>c</sup>	10	91	7	78	7	70	4	100	3	100	4	100	35	85
Unknown	0	0	0	0	1	10	0	0	0	0	0	0	1	2
Total	11		9		10		4		3		4		41	
						White								
Very low birth weight <sup>a</sup>	0	0	0	0	0	0	1	11	0	0	0	0	1	2
Low birth weight <sup>b</sup>	1	11	1	10	2	22	4	44	4	67	0	0	12	26
Normal <sup>c</sup>	8	89	9	90	7	78	4	44	2	33	3	100	33	72
Unknown	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total	9		10		9		9		6		3		46	

Note: Because of rounding, column percentages may not total 100%. Numbers and percentages are reported for total number of HIV-exposed infants. Other and unknown races are excluded due to small numbers.

<sup>a</sup> Very low birth weight is defined as less than 1,500 grams.

<sup>b</sup> Low birth weight is defined as weight between 1,500 and 2,499 grams.

<sup>c</sup> Normal birth weight is defined as weight of 2,500 grams or greater.

					Ye	ar of inf	ant's bi	rth					Cumu	ılative
Gestational age by	20	05	20	06	20	007	20	08	20	09	20	010	То	tal
weeks	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
				В	lack/Af	rican Ar	nerican			•				
Preterm <sup>a</sup>	27	21	40	31	27	31	24	26	33	31	10	16	161	26
Term <sup>ь</sup>	91	70	90	69	54	61	65	70	72	69	52	84	424	70
Unknown	12	9	0	0	7	8	4	4	0	0	0	0	23	4
Total	130		130		88		93		105		62		608	
					Hisp	anic/Lat	ino							
Pretermª	2	18	1	11	3	30	2	50	0	0	0	0	8	20
Term <sup>♭</sup>	9	82	7	78	3	30	2	50	3	100	4	100	28	68
Unknown	0	0	1	11	4	40	0	0	0	0	0	0	5	12
Total	11		9		10		4		3		4		41	
						White								
Pretermª	2	22	1	10	2	22	5	56	1	17	1	33	12	26
Term <sup>♭</sup>	6	67	8	80	7	78	4	44	5	83	2	67	32	70
Unknown	1	11	1	10	0	0	0	0	0	0	0	0	2	4
Total	9		10		9		9		6	1	3		46	

Note: Because of rounding, column percentages may not total 100%. Numbers and percentages are reported for total number of HIV-exposed infants. Other and unknown races are excluded due to small numbers.

<sup>a</sup> Preterm is defined as gestational age of less than 37 weeks.

<sup>b</sup> Term is defined as gestational age of greater than or equal to 37 weeks.

Table 20. Birth defects in 2005-2010 – G		t year of	life in cr	ildren b	orn to H	IIV-infect	ted wom	ien, by r	ace/ethr	licity and	l year of	'infant's	birth,	
					Ye	ar of inf	ant's bi	rth					Cumu	lative
Birth defects in first	20	05	20	06	20	07	20	08	20	09	20	010	То	tal
year of life	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
				В	lack/Af	rican Ar	nerican							
Yes	0	0	0	0	2	2	1	1	0	0	0	0	3	<1
No	9	7	2	2	19	22	20	22	10	10	1	2	61	10
Unknown	121	93	128	98	67	76	72	77	95	90	61	98	544	89
Total	130		130		88		93		105		62		608	
					Hisp	anic/Lat	tino							
Yes	0	0	0	0	0	0	0	0	0	0	0	0	0	0
No	1	9	0	0	4	40	0	0	0	0	0	0	5	12
Unknown	10	91	9	100	6	60	4	100	3	100	4	100	36	88
Total	11		9		10		4		3		4		41	
		<u>.</u>				White		•	°	·			·	
Yes	0	0	0	0	0	0	0	0	0	0	0	0	0	0
No	0	0	0	0	1	11	0	0	0	0	0	0	1	2
Unknown	9	100	10	100	8	89	9	100	6	100	3	100	45	98
Total	9		10		9		9		6		3		46	

Table 20. Rirth defects in the first year of life in children born to HIV-infected women, by race/ethnicity and year of infant's birth


Note: Because of rounding, column percentages may not total 100%. Numbers and percentages are reported for total number of HIV-exposed infants. Other and unknown races are excluded due to small numbers.

					Ye	ar of inf	fant's bi	rth					Cumu	lative
	20	05	20	06	20	007	20	08	20	09	20	010	То	tal
Type of facility	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
				BI	ack/Afı	rican An	nerican							
Private care (OB/GYN, midwife)	13	10	9	7	7	8	2	2	7	7	1	2	39	7
HMO clinic	0	0	2	2	0	0	0	0	0	0	0	0	2	<1
OB/GYN clinic	48	38	57	45	27	32	15	17	37	36	33	53	217	37
Adult HIV specialty clinic	2	2	2	2	0	0	0	0	0	0	0	0	4	1
Correctional facility	2	2	2	2	1	1	0	0	0	0	0	0	5	1
Other	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Unknown	62	49	55	43	49	58	73	81	60	58	28	45	327	55
Total	127		127		84		90		104		62		594	
					Hispa	anic/Lat	ino							
Private care (OB/GYN, midwife)	2	18	0	0	1	11	0	0	0	0	0	0	3	8
HMO clinic	1	9	0	0	0	0	0	0	0	0	0	0	1	3
OB/GYN clinic	4	36	3	33	6	67	1	25	0	0	1	25	15	38
Adult HIV specialty clinic	0	0	1	11	0	0	0	0	0	0	0	0	1	3
Correctional facility	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Unknown	4	36	5	56	2	22	3	75	3	100	3	75	20	50
Total	11		9		9		4		3		4		40	
	<u> </u>					White	<u> </u>							
Private care (OB/GYN, midwife)	2	22	0	0	1	11	1	11	0	0	0	0	4	9
HMO clinic	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OB/GYN clinic	1	11	6	60	3	33	2	22	2	33	0	0	14	30
Adult HIV specialty clinic	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Correctional facility	1	11	1	10	0	0	0	0	0	0	0	0	2	4
Other	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Unknown	5	56	3	30	5	56	6	67	4	67	3	100	26	57
Total	9		10		9		9		6		3		46	


Note: Because of rounding, column percentages may not total 100%. Numbers and percentages are reported for total number of HIV-infected pregnancies. Other and unknown races are excluded due to small numbers.

### **Figures**





























#### Georgia Department of Public Health





















































# Appendix A - Georgia EPS Tertiary Care Facilities

Facility	City	Health District
Emory Crawford Long Hospital	Atlanta	3-2
Grady Memorial Hospital	Atlanta	3-2
Medical Center of Central Georgia	Macon	5-2
Medical College of Georgia	Augusta	6
Memorial Health University	Savannah	9-1
Phoebe Putney Memorial Hospital	Albany	8-2
The Medical Center	Columbus	7

# Appendix B - Enhanced Perinatal Abstraction Form

Infant State No.\_\_\_\_\_

U.S. Department of Health & Human Services Centers for Disease Control and Prevention	En	hanced Perinatal Surv	veillance (	EPS)	
	1			Form Approved OMB	No. 0920-0573 Exp. Date 1/31/2013
New 🔲	Initials of person c	completing the form (Print legibly.)	Information c	complete for analysis?	
Updated 🗖			Yes 🗆	No	
Date form completed (eg. ab	straction concluded)	Date form received by main facil	ity	Date case was report	rted
// (mm	/dd/yyyy)	// (mm/dd/	/ууу)	//	(mm/dd/yyyy)
How was the infant first iden	ntified?	•		·	
Routine case reportir	ng—pediatric report	Active case finding f	or enhanced per	inatal surveillance	
Routine case reportir	ng—maternal report	Laboratory reporting			
Birth registry match		Other than routine s	urveillance activi	ties (Specify.)	
		s the child adopted, in foster care,	or abandoned?	<b>,</b>	
Yes 🖵 No 🖵	Not applicable				
1. Records abstracted (Re (1 = Abstracted, 2 = Atter		ailable, <b>3</b> = Not abstracted, <b>4</b> = Atterr	pted—will try ag	jain)	
Prenatal care rec	ords	Pediatric medical	records (non-HI	IV clinic or provider)	
Maternal HIV clini	ic records	Birth certificate			
Labor and deliver	y records	Death certificate			
Pediatric birth rec	ords	Health departme	nt records		
Pediatric HIV med	dical records	Other (Specify.)			

## **Demographic Information**

2. Infant					
Reporting state (Required)	City No.		Date of birth (Required	I)	Sex at birth
				_ (mm/dd/yyyy)	M F
State No. (Required)	Sounde	x code	Date of death		
			//	_ (mm/dd/yyyy)	
3. Mother					
Reporting state	City No.		Date of birth		
				_ (mm/dd/yyyy)	
State No.	Sounde	x code	Date of death		
				_ (mm/dd/yyyy)	
4. Mother's country of birth		4a. If mother's country of	f birth is not specified	, list continent o	f birth if known.
5. Mother's Hispanic ethnicity		6. Mother's 1	ace (Mark all that apply	y.)	
Tes Yes		Ameri	can Indian/Alaska Native	Hawaiian/O	ther Pacific Islander
D No		Asian		White	
			African American		
			(Specify.)		
7. Marital status (at time of deliver	y) 🖵 :	Single 🔲 Divorced 🛄 N	larried 🖵 Separated	U Widowed	Unknown
This report to the Centers for Disease Control and Preve	ention (CDC) is	authorized by law (Sections 304 and 306 of t	he Public Health Service Act. 42 US	SC 242b and 242k). Respo	nse in this case is voluntary for federal
government purposes, but may be mandatory under sta	te and local sta	tutes. Your cooperation is necessary for the u	understanding and control of HIV/AII	DS. Information in CDC's H	IIV/AIDS surveillance system that would
permit identification of any individual on whom a record department, and will not otherwise be disclosed or relea					
Public reporting burden of this collection of information is					
needed, and completing and reviewing the collection of control number. Send comments regarding this burden e					
D-74, Atlanta, GA 30333, ATTN: PRA (0920-0573). Do			including suggestions for reducing i		Clearance Onicer, 1000 Cinton Road, NIS
04/02/2006					Page 1 of

				Infai	nt State No.		
8. Mother's HIV risk factor (Mark al	that apply )	Hatarosa	Yual c	contact with	(cont)		
Injection drug use	r triat apply.)	_			factor not spe	cified	
Heterosexual contact with		Hemophilia v			-	cined	
injection drug user		Receipt of tra					
bisexual male		Receipt of tra			raan ar artifiai	al incomination)	
male with hemophilia with document	antad LIV(	Perinatal exp	-	-	-	-	
Transfusion recipient with documen			JSure	(i.e. mourie	r was permata	iny mected)	
transfusion recipient with document				Laiste (Disse		RR coordinator in yo	
	ed HIV Intection	Uther docum			uss with the N	RR coordinator in ye	our state.)
		Prenatal Care		<u></u>			
9. Did mother receive any prenatal c	are for this preg			10. Date	e of first pre	natal care visit	
Yes No (Go to 15.)	Not documented (	Go to 15.) 🖵 Unknown			_//	(mm/dd/yyy	y)
11. Month of pregnancy during which	h prenatal care be	egan		12. Date	e of last prei	natal care visit b	efore delivery
(mos) (99 = unknown) <b>or</b>	(in weeks	s if month is not noted in cha	art)	_		(mm/dd/yy	/уу)
13. Number of prenatal care visits _	(99 =	unknown)					
14. In what type of facility was prena	atal care primari	ly delivered? (Check on	ly on	e box.)			
OB/GYN clinic	Private	care (OB/GYN, midwife)		Oth	er (Specify.) _		
Adult HIV specialty clinic	Correct	ional facility		🔲 Not	documented		
HMO clinic (for prenatal care)	ACTG S	site		🔲 Unł	nown		
15. Was the mother screened for any (Check test performed before birth Yes Group B strep	n, but closest to da <b>Date</b> (r	te of delivery or admission	on to lo			Record not avail	able Unknown
Hepatitis B (HBsAg)	/	_/					
Rubella		_/					
Syphilis	/	_/					
16. Diagnosis (for the mother) of the	following conditi	ions during this pregna	ncy (	or at the	time of labo	r and delivery	
(See Instructions for Data Abstrac	tion for definitions. Yes	Date of diagnosis		No N	ot documente	ed Record not ava	ilable Unknown
Bacterial vaginosis		(mm/dd/yyyy) / /					
Chlamydia trachomatis infection			_				
Genital herpes							
Gonorrhea							
Group B strep							
Hepatitis B (HbsAg+)				Ē	Ē	Ē	
Hepatitis C						Ē	
PID							
		//					
Syphilis		//					
Trichomoniasis		//					
17. Mother's reproductive history No. of previous pregna	ancies	No. of previous mis	carria	ges or still	oirths		
No. of previous live bir	ths	No. of previous ind	uced a	abortions o	<b>r</b> Tota	I No. of previous ab	ortions
18. Complete the chart for all sibling	<u>,</u> s.		_				

### Infant State No.\_\_\_\_\_

	Date of birth (mm/dd/yyyy)	Age (yrs: mos as of mm/yyyy)	HIV serostatus (See list.)	State No.	City No.				
Sib 1	//	:as of/							
Sib 2	//	:as of/							
Sib 3	//	:as of/							
Sib 4	//	:as of/							
Sib 5	//	:as of/							
Sib 6	//	:as of/							
	HIV serostatus: 1 = Infected, 2 = Not infected, 3 = Indeterminate, 9 = Not documented U=Unknown								

#### Substance Use

19. Was substance use during pregnancy noted in the n Yes No (Go to 20.) Record not available									
19a. If yes, indicate which substances were used during pregnancy. (Check all that apply.)									
	<ul> <li>Marijuana (cannabis, THC, cannabinoids)</li> <li>Methadone</li> <li>Methamphetamines</li> <li>Nicotine (any tobacco product)</li> </ul>	<ul> <li>Opiates</li> <li>Other (Specify.)</li> <li>Specific drug(s) not documented</li> </ul>							
19b. If substances used, were any injected?	19b. If substances used, were any injected?								
20. Was a toxicology screen done on the mother (either	during pregnancy or at the time of delive	ery)?							
Yes, positive result (Check all that apply.)									
<ul> <li>Alcohol</li> <li>Cocaine</li> <li>Amphetamines</li> <li>Crack cocaine</li> <li>Barbiturates</li> <li>Hallucinogens</li> <li>Benzodiazepines</li> <li>Heroin</li> </ul>	<ul> <li>Marijuana (cannabis, THC, cannabinoids)</li> <li>Methadone</li> <li>Methamphetamines</li> <li>Nicotine (any tobacco product)</li> </ul>	<ul> <li>Opiates</li> <li>Other (Specify.)</li> <li>Specific drug(s) not documented</li> </ul>							
	creen not documented								
21. Was a toxicology screen done on the infant at birth Yes, positive result (Check all that apply.)	?								
<ul> <li>Alcohol</li> <li>Cocaine</li> <li>Amphetamines</li> <li>Crack cocaine</li> <li>Barbiturates</li> <li>Hallucinogens</li> <li>Benzodiazepines</li> <li>Heroin</li> </ul>	<ul> <li>Marijuana (cannabis, THC, cannabinoids)</li> <li>Methadone</li> <li>Methamphetamines</li> <li>Nicotine (any tobacco product)</li> </ul>	<ul> <li>Opiates</li> <li>Other (Specify.)</li> <li>Specific drug(s) not documented</li> </ul>							
Yes, negative result No Toxicology so	creen not documented								
22. If the results of the toxocology screen indicated substance use, was the mother referred for treatment (during or after this pregnancy)? Yes No Not documented Unknown									

Infant	State	No
imani	State	110.

## Maternal Testing/Clinical Information

23. Mother's HIV serostatus			
Mother refused HIV testing	sitive before child's birth, date unkn	own	
HIV-positive before this pregnancy	sitive after child's birth		
HIV-positive during this pregnancy	sitive, date unknown		
HIV-positive at time of delivery			
24. Date of mother's first positive result from confirmate	orv testing (WB or IFA)		
//(mm/dd/yyyy)			
25. Results of mother's HIV screening during pregnancy	7		
Results	Test	Date	
(See list in 26.)	(See list in 26.)	(mm/dd/yyyy)	
25a. First screening			
		, ,	
		//	
25b. Second screening (if result was negative, or moth	er refused first screening)		
		//	
25c. Third screening (if result was negative, or mother	refused second screening)		
		//	
26. Mother's HIV screening at time of labor and delivery			
Results	Test	Date of results in labor and delivery	Time of results in labor and delivery
		Date of results in labor and delivery (mm/dd/yyyy)	Time of results in labor and delivery (See military time.)
Results	Test	labor and delivery	labor and delivery
Results (See list.)	Test	labor and delivery (mm/dd/yyyy)	labor and delivery
Results (See list.) 26a. First screening	Test	labor and delivery	labor and delivery
Results (See list.)	Test	labor and delivery (mm/dd/yyyy)	labor and delivery
Results (See list.) 26a. First screening 26b. Second screening (if applicable)	Test (See list.)	labor and delivery (mm/dd/yyyy)	labor and delivery
Results (See list.) 26a. First screening 26b. Second screening (if applicable)	Test (See list.)	labor and delivery (mm/dd/yyyy)	labor and delivery
Results (See list.) 26a. First screening 26b. Second screening (if applicable)	Test (See list.)	labor and delivery (mm/dd/yyyy)	labor and delivery
Results (See list.) 26a. First screening 26b. Second screening (if applicable)	Test (See list.)	labor and delivery (mm/dd/yyyy)	labor and delivery
Results (See list.) 26a. First screening 26b. Second screening (if applicable) 26c. Confirmatory test Results	Test (See list.)	labor and delivery (mm/dd/yyyy)	labor and delivery (See military time.) :
Results (See list.) 26a. First screening 26b. Second screening (if applicable) 26c. Confirmatory test Results Positive	Test (See list.)	labor and delivery (mm/dd/yyyy)	labor and delivery         (See military time.)        :        :        :        :        :        :        :
Results (See list.)         26a. First screening         26b. Second screening (if applicable)         26c. Confirmatory test         Results         Positive         Negative         Indeterminate	Test (See list.)	labor and delivery (mm/dd/yyyy)	labor and delivery         (See military time.)        :        :        :        :        :        :        :        :        :
Results (See list.)         26a. First screening         26b. Second screening (if applicable)         26c. Confirmatory test         Results         Positive         Negative         Indeterminate         Results not available	Test (See list.)	labor and delivery (mm/dd/yyyy)	labor and delivery         (See military time.)        :        :        :        :        :        :        :
Results (See list.)         26a. First screening         26b. Second screening (if applicable)         26c. Confirmatory test         Results         Positive         Negative         Indeterminate	Test (See list.)	labor and delivery (mm/dd/yyyy)	labor and delivery         (See military time.)        :        :        :        :        :        :        :        :        :
Results (See list.)         26a. First screening         26b. Second screening (if applicable)         26c. Confirmatory test         Results         Positive         Negative         Indeterminate         Results not available         Not tested	Test (See list.)	labor and delivery (mm/dd/yyyy)	labor and delivery         (See military time.)        :        :        :        :        :

r

Infant	State	No.	
--------	-------	-----	--

27. Were CD4 counts determined during pregnancy or within 6 months before pregnancy?										
	Yes No (Go to 28.) Not documented (Go to 28.) Record not available (Go to 28.) Unknown									
27a. I	E 27a. If yes, list below. (If more than 3 counts in record, prioritize the CD4 counts, starting with the count closest to delivery. If CD4 counts were not determined during pregnancy, record CD4 counts within 6 months before pregnancy if possible.)									
	Example: CD4 count of 174 cells/µL, 12%, August 12, 2000, would be recorded as <u>174</u> cells/µL <u>08/12/2000</u>									
			I			<u>12</u>	%	08/12/2000		
CD4 result	Unit	Date blood drawn (mm/dd/yyyy)	CD4 result	Unit	Date blood drawn (mm/dd/yyyy)	CD4 result	Unit	Date blood drawn (mm/dd/yyyy)		
	cells/µL	//		cells/µL	//		cells/µL	//		
	%	//		%	//		%	//		
28. Were v	<u></u>	<u> </u>	, <b>.</b>	_	mother during pregn     Record not available (Ge			hs before pregnancy?		
				· •	<b>itize</b> the results of viral le nancy, record viral loads	,	0			
	Result	t in No. of copies/mL	Result in	logs	Date blood drawn (mm/dd/yyyy)					
					//					
					//					
					//					
29. What v	vas the mot	her's most advanced	HIV serostatı	is during	pregnancy?					
	HIV infectio	on, not AIDS	🔲 AIDS, CD	4 criteria o	nly 🗖 Al	IDS, indicator co	ondition			
	HIV-negativ	ve	Not docur	mented		ecord not availa	ble	Unknown		
30. Was th	e mother's	HIV serostatus noted	in her prena	tal care n	nedical records?					
	30. Was the mother's HIV serostatus noted in her prenatal care medical records?									

# Antiretroviral Therapy

31.	31. Were antiretroviral drugs prescribed for the mother during this pregnancy?									
Yes (Complete table.) No (Go to 31		31a.) UNot docur	mented (Go to 32.)	Record not available (Go to 32.)						
	Drug name (See list on p. 8.)	Other (specify)	Drug refused	Date drug started (mm/dd/yyyy)	Gestational age drug started (weeks; round down)	<b>Drug stopped</b> Yes No ND	Date stopped (if yes in preceding column) (mm/dd/yyyy)	Stop codes (See list on p. 8.)		
i				//			//			
ii	· · · · · · · · · · · · · · · · · · ·			//			//			
iii				//			//			
iv				//			//			
v				//			//			
vi				//			//			
vii				//			//			
viii				//			//			
	(After completing table, go to 32.)									
	31a. If no antiretroviral drug was prescribed during pregnancy, check reason.         No prenatal care       Mother known to be HIV-negative during pregnancy         HIV serostatus of mother unknown       Mother refused									

04/02/2006

-1

## Georgia Department of Public Health

	Infant State No							
<b>32. Was mother's HIV set</b> Yes, HIV-positive	rostatus noted i Yes, HIV-neg	n her labor a gative	nd delivery recor		Unknown			
33. Did mother receive antiretroviral drugs during labor and delivery? Yes (Complete table.) No (Go to 33a.) Not documented (Go to 34.) Record not available (Go to 34.) Unknown								
<b>Drug Name</b> (See list.)	Other (specify)	Drug refused	Date receive (mm/dd/yyy)		Time received (See military time.)	T <u>y</u> Oral	ype of adminis	<b>stration</b> Not documented
i			//		:			
ii			//		:			
iii			//		:			
iv			//		:			
v								
vi								
vii					;			
(After completing table, go to		-			— —·— — Military time: noor	_	aidniaht = 00	
		noived durin	a labor and daling	any aboat no		ı − ı∠.00, fi	manight = 00	5.00
33a. If no antiretroviral drug was received during labor and delivery, check reason.         □       Precipitous delivery/STAT         □       HIV serostatus of mother         □       Mother tested HIV-negative         □       Unknown         □       Birth not in hospital         □       Not documented         □       Unknown								
34. Was mother referred for HIV care after delivery?         Yes       No (Go to 36.)         Not documented (Go to 36.)         Record not available (Go to 36.)         Unknown								
35. If yes, indicate first CD4 result or first viral load after discharge from hospital (up to 6 months after discharge).								
35a. CD4 result U Not done U Not available 35b. Viral load U Not done U Not available								
Result         Unit         Date blood drawn (mm/dd/yyyy)         Result in copies/mL         Result in logs         Date blood draw (mm/dd/yyyy)								
cells/µL//						_/		
	%//							
Birth History								
36. Type of birth □ Single □ Twin □ ≥3 □ Record not available □ Unknown								
37. Birth information	Birth not in hos	pital 🔲	Record not available	e				
	Time     Date (mm/dd/yyyy)     Time     Date (mm/dd/yyyy)							mm/dd/yyyy)
(See military time.) (See military time.)								
Onset of labor        //         Rupture of membranes        ///						_/		
Admission to labor and	delivery:		'/	Delivery		:	/	_/
	Military	/ time: noon = ·	12:00; midnight = 00:	00				
38. Gestational age at time of delivery (in weeks; round down to nearest whole week)								
<b>39. Mode of delivery</b>		39a. If Cesa	rean delivery, mar	k all the follo	wing indications t	hat apply.	,	
Vaginal (Go to 40.)       Unknown       HIV indication (high viral load)       Fetal distress								
			Previous Cesarean (r	an (repeat)				
Non-elective Cesarean delivery     Malpresentation (								
Cesarean delivery, unknown type								
Record not available	(Go to 41.)		Nother's or physician	's preference	Not specifie	ed		
40. Instrument used INONE Forceps Vacuum Forceps and vacuum Not specified								

Page 6 of 8

	Infant State No			
41. Child's birth weight (lbs/oz or grams)	42. Was mother's HIV serostatus noted on the child's birth record?			
lbs oz <b>or</b> grams	Yes, HIV-positive Yes, HIV-negative Record not available Unknown			

## **Pediatric History**

43.	43. Were antiretroviral drugs prescribed for the child during the first 6 weeks of life? Yes (Complete table.) No (Go to 43a.) Not documented (Go to 44.) Record not available (Go to 44.) Unknown							
				·				
		<b>Other</b> pecify)	Drug refused	Date drug started (mm/dd/yyyy)	Time started (See military time.)	ART Completed? Yes No ND UNK	Stop date (if therapy not complete (mm/dd/yyyy)	ed) Stop codes (See list on p. 8.)
i				//	;		//	
ii		<u></u> .		//	;		//	
iii				//	:		//	
iv				//	:		//	
v	<u> </u>	<del> </del>		//	;		//	
vi				//	:		//	
vii				//	:		//	
viii				//	:		//	
					Military time: r	noon = 12:00; mid	night = 00:00	
	43a. If no antiret	oviral drug wa	as prescri	bed during the first	6 weeks of life, in	ndicate reason.		
	HIV seros	status of mother u	Inknown	_	Other (Speci	ify.)		
	Mother ki	nown to be HIV-n	egative duri	ng pregnancy	Not documented			
	D Mother re		0					
44.	Infant's HIV antil	odv testing			45. Results of I	DNA/RNA scre	ening	
	Results	Test		Date blood drawn	Resul		-	blood drawn
	(See list.)	(See list	,	(mm/dd/yyyy)	(See list in	n 44.) Di	NA RNA (m	m/dd/yyyy)
	i		<u> </u>	//	i			/
	ii		<u> </u>	//	ii		] []/_	/
	iii	. <u></u>		//	iii		] []/_	/
	Results Positive	Tests Rapid			iv		] []/_	/
	Negative	Expedited	EIA		v		]/_	/
	Indeterminate Results not available Infant not tested Mother refused Unknown	EIA Not documente	ed					
46. '	46. What is the child's current HIV infection status?			47. If child's HIV serostatus is indeterminate, indicate reason.				
	AIDS Confirmed HIV infected (not AIDS)			Moved from state				
	HIV-negative Indeterminate as of			Provider out of state Died before serostatus determined				
		/_	/	(mm/dd/yyyy)	Child <	18 months of age	Not documented	
48.	Was PCP prophyla	xis prescribed	during t	he first year of life?	49.Was child breastfed?			
	Yes Date received/_/				Yes Durationdaysweeks			
	No Not documented Record not available				Duration not documented			
					🗖 No	Not documer	ted Record not a	available

04/02/2006

		Infant State No			
		Unknown			
50. Were birth defects noted dur	ing the first year of life?	50a. If yes, specify type(s).			
	Yes       No (Go to 51.)       Record not available (Go to 51.)       Code Code				
	Unknown				
51. If child is deceased, please ob appears on death certificate.)	tain the following from the death	certificate. (Print legibly. Include ICD	-9 or ICD-10 codes only if code		
	Cause of death				
Immediate					
Underlying					
Underlying					
Contributing					
Note. Please be sure that a data	ate of death has been entered on pag	e 1, under Demographic Information	(2. Infant).		
	clinical information you consider date and source of the informatio	relevant to the overall understandin n.	ng of this child's HIV exposure		
Antiretroviral drugs and s	top codes				
NNRTI	NRTI (cont)	Protease inhibitor	Other		
Delavirdine (Peserinter)	Enzicom (Abacavir/3TC Kivova)	Ampropayir (Agenerase)	Adefovir dinivovil (his POM		

#### Delavirdine (Rescriptor) Epzicom (Abacavir/3TC, Kivexa) Amprenavir (Agenerase) Adefovir dipivoxil (bis-POM, Efavirenz (Sustiva) Lamivudine (3TC, Epivir) Darunavir (Prezista) PMEA, Preveon) Nevirapine (Viramune, NVP) Stavudine (d4T, Zerit) Indinavir (Crixivan) Atripla (Efavirenz & Tenofovir & Kaletra (Lopinavir, Ritonavir) Trizivir (AZT & 3TC & Abacavir) Emtricitabine) NRTI Truvada (Tenofovir DF/Emtricitabine) Lexiva (Fosamprenavir) Fuzeon (Enfuvirtide or T20) Abacavir (Ziagen, ABC) Videx<sup>®</sup> EC (Didanosine) Nelfinavir (Viracept) Hydroxyurea (Droxia, Hydrea) Combivir (AZT & 3TC) Viread (Tenofovir) Reyataz (Atazanavir or ATV) Intelence Didanosine (ddl, Videx) Ritonavir (Norvir) Zalcitabine (ddC, Hivid) Selzentry Emtriva (Emtricitabine or FTC) Zidovudine (AZT, Retrovir) Saguinavir (Fortavase, Invirase) Isentress Tipranavir (Aptivus) If an antiretroviral drug not on this list, call CDC Stop codes (2 codes allowed; if more, choose the 2 most important) **S1** = Adverse events (toxicity, lack of tolerance) S6 = Strategic treatment interruption (planned drug holiday) S11 = Improving effectiveness **S12** = Improving convenience S2 = ART completed S7 = Drug interactions S3 = Drug resistance detected S8 = Mother's choice **S13** = Reason not indicated; unknown S4 = Poor adherence S9 = Pregnancy S14 = Mother couldn't afford drugs S5 = Inadequate effectiveness S10 = Child determined not to be HIV infected Sxx = Other reason

#### List of abbreviations

CTG	AIDS Clinical Trials Group	NRTI	nucleoside reverse transcriptase inhibitor
RT	antiretroviral therapy	NRR	no risk factor reported
Ą	enzyme immunoassay	OB-GYN	obstetric-gynecologic or obstetrician-gynecologist
ARS	HIV/AIDS Reporting System	PCP	Pneumocystis jirovecii pneumonia [jirovecii is now preferred to carinii;
ΛO	health maintenance organization		abbreviation is the same]
D-9	International Classification of Diseases, Ninth Revision	PI	protease inhibitor
D -10	International Classification of Diseases, Tenth Revision	PID	pelvic inflammatory disease
4	immunofluorescent assay	STAT	immediately (statim)
)	not documented	WB	Western blot
IRTI	nonnucleoside reverse transcriptase inhibitor		
	RT A ARS 40 D-9 D -10 A 0	RTantiretroviral therapy enzyme immunoassay RSHIV/AIDS Reporting SystemMOhealth maintenance organizationD-9International Classification of Diseases, Ninth RevisionD-10International Classification of Diseases, Tenth RevisionAimmunofluorescent assayDnot documented	RT       antiretroviral therapy       NRR         A       enzyme immunoassay       OB-GYN         RS       HIV/AIDS Reporting System       PCP         MO       health maintenance organization       PCP         D-9       International Classification of Diseases, Ninth Revision       PI         D-10       International Classification of Diseases, Tenth Revision       PID         A       immunofluorescent assay       STAT         D       not documented       WB

04/02/2006

Page 8 of 8



HIV/AIDS Epidemiology Program Enhanced Perinatal Surveillance Report, Georgia 2005-2010